Vimta Labs Ltd.
Snapshot View

315.05 -8.90 ▼-2.8%

02 August 2021, 04:00:00 P.M.
Volume: 9,430

Overview View Details

Sector Miscellaneous Compare with Sector peers
Industry Miscellaneous Compare with Industry peers
Website http://www.vimta.com
Financial Indicators
Market Cap 701.37 Cr.
Earnings per share (EPS) 14.21 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) 22.32 Trailing Twelve Months Ending 2021-06
Industry PE 114.29 Trailing Twelve Months Ending 2021-06
Book Value / Share 91.57 Trailing Twelve Months Ending 2021-06
Price to Book Value 3.46 Calculated using Price: 317.25
Dividend Yield 0.63 Period Ending 2021-03
No. of Shares Subscribed 2.21 Cr. 22,107,810 Shares
FaceValue 2
Company Profile

Vimta Labs is India’s leading contract research and testing organization. Established in 1984, Vimta has an envious track record of serving several market leaders across the globe.

Vimta supports regulatory authorities in mandatory certification of food and agri products exported from India. Vimta assists the food industry commissions for nutritional labelling, food safety evaluations, trace analysis and shelf life studies.

Vimta has a team of 684 professionals comprising 446 scientists in various disciplines such as chemistry, pharma, medicine, microbiology, molecular biology and informatics. The team is slated to double in next three years.

Vimta is a multi-site organization with more than 300,000 sqft world class laboratory facilities. The technologies deployed at Vimta are current and leading edge, duly validated.

Vimta has over 12 years of experience in providing preclinical services to Pharma companies world-wide accordance with the guidelines prescribed by international agencies.

Vimta has a state-of-art building of Class 10,000 Pre-clinical facility with a total built up area of 33,000 sq.ft. with 32 rodent experimental rooms, 5 procedure rooms, separate quarantine facility and distinct non-rodent facility with 48 SS kennels with a comfortable perch, liberal exercise area.

It provides services in pharmacology, toxicology and DMPK areas. The toxicology services include but not limited to in-vivo and in-vitro genotoxicity, acute to chronic toxicity, carcinogenicity, reproductive toxicity studies, safety pharmacology, and immunotoxicology. Pharmacology services are available in various therapeutics areas such as pain & inflammation, metabolic disorders, respiratory, CNS, and xenograft & allograft models for oncology. In addition to the regulatory studies we use tailor-made in vitro and in vivo ADME techniques to help profile your drug candidate in both rodent and non-rodent animals models.

Services offered by the company:

  • Advanced Molecular Biology
  • Food and Agriculture
  • Drugs & Pharma
  • Water
  • Environmental Assessments
  • Clinical Research
  • Clinical Reference Lab Services
  • Preclinical Research
  • Genomics Online Ordering

 Achievements/ recognition

  •    NABL as per ISO 15189:2007

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-2.75%
1 Week
-0.60%
1 Month
+18.11%
3 Month
+22.73%
6 Month
+81.12%
1 Year
+201.34%
2 Year
+210.24%
5 Year
+273.50%
2 years 2020-03 2021-03
Return on Equity (%) 3.96 11.66
Return on Capital Employed (%) 5.84 14.25
Return on Assets (%) 2.79 8.25

Balance Sheet View Details

Particulars 2 years 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 173 194
Non Curr. Liab. 15 25
Curr. Liab. 58 54
Minority Int.
Equity & Liab. 245 273
Non Curr. Assets 149 163
Curr. Assets 96 111
Misc. Exp. not W/O
Total Assets 245 273

Profit Loss View Details

Particulars 2 years 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 181 211
Other Income 3 1
Total Income 184 212
Total Expenditure -151 -158
PBIDT 33 54
Interest -4 -2
Depreciation -21 -23
Taxation -1 -7
Exceptional Items
PAT 7 21

Cash Flow View Details

Particulars 2 years 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 24 37
Cash Fr. Inv. -21 -32
Cash Fr. Finan. -1 -5
Net Change 3 1
Cash & Cash Eqvt 6 6

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 37.41 37.46 37.46 37.46 37.46 37.46 37.46 37.46 37.46
Public 62.59 62.54 62.54 62.54 62.54 62.54 62.54 62.54 62.54
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 02 Aug 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding receipt of Information for loss of share certificate
Fri, 23 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
Standalone and Consolidated Unaudited Financial Results for the first quarter ended 30th June 2021 published in Financial Express (English) and Andhra Prabha (Telugu) on 23rd July 2021
Thu, 22 Jul 2021
Standalone And Consolidated Unaudited Financial Results For The 1St Quarter Ended 30Th June 2021 Along With Limited Review Report
Regulation 33 and 30 of SEBI (Listing obligations and disclosure requirements) 2015 please find enclosed herewith Standalone and Consolidated Unaudited Financial Results for the 1st quarter ended 30th June 2021 along with Limited Review Report

Technical Scans View Details

Mon, 02 Aug 2021
Close Crossing Last Month Close from Above Close Crossing Last Month Close from Above
Closing Below Previous Low Closing Below Previous Low
Close Within 52 Week High Zone Close Within 52 Week High Zone
William %R Trending Down William %R Trending Down
Fri, 30 Jul 2021
Close Within 52 Week High Zone Close Within 52 Week High Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Syngene International Ltd. 25,650.98 640.00 +0.1%
Quess Corp Ltd. 13,011.98 880.65 +1.6%
RattanIndia Enterprises Ltd. 9,150.62 66.20 -1.0%
Sun Pharma Advanced Research Company Ltd. 7,350.43 280.50 +3.8%
SIS Ltd. 7,239.26 493.25 +2.6%
TeamLease Services Ltd. 7,073.96 4,137.60 -2.8%
Just Dial Ltd. 6,021.63 965.50 +0.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Syngene International Ltd. Consolidated 2021-06 60.47 640.00 +0.1%
Quess Corp Ltd. Consolidated 2021-03 224.82 880.65 +1.6%
RattanIndia Enterprises Ltd. Consolidated 2021-03 0.00 66.20 -1.0%
Sun Pharma Advanced Research Company Ltd. Standalone 2021-06 0.00 280.50 +3.8%
SIS Ltd. Consolidated 2021-06 19.60 493.25 +2.6%
TeamLease Services Ltd. Consolidated 2021-06 80.87 4,137.60 -2.8%
Just Dial Ltd. Consolidated 2021-06 47.30 965.50 +0.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Syngene International Ltd. Consolidated 2021-06 9.09 640.00 +0.1%
Quess Corp Ltd. Consolidated 2021-03 5.55 880.65 +1.6%
RattanIndia Enterprises Ltd. Consolidated 2021-03 107.85 66.20 -1.0%
Sun Pharma Advanced Research Company Ltd. Standalone 2021-06 -31.80 280.50 +3.8%
SIS Ltd. Consolidated 2021-06 4.06 493.25 +2.6%
TeamLease Services Ltd. Consolidated 2021-06 10.43 4,137.60 -2.8%
Just Dial Ltd. Consolidated 2021-06 4.77 965.50 +0.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Syngene International Ltd. Consolidated 2021-03 0.28 640.00 +0.1%
Quess Corp Ltd. Consolidated 2020-03 0.51 880.65 +1.6%
RattanIndia Enterprises Ltd. Consolidated 2020-03 0.00 66.20 -1.0%
Sun Pharma Advanced Research Company Ltd. Standalone 2020-03 -3.67 280.50 +3.8%
SIS Ltd. Consolidated 2021-03 0.74 493.25 +2.6%
TeamLease Services Ltd. Consolidated 2020-03 0.14 4,137.60 -2.8%
Just Dial Ltd. Consolidated 2020-03 0.00 965.50 +0.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Syngene International Ltd. Consolidated 2021-03 16.59 640.00 +0.1%
Quess Corp Ltd. Consolidated 2020-03 -16.80 880.65 +1.6%
RattanIndia Enterprises Ltd. Consolidated 2020-03 -0.24 66.20 -1.0%
Sun Pharma Advanced Research Company Ltd. Standalone 2020-03 -225.08 280.50 +3.8%
SIS Ltd. Consolidated 2021-03 23.02 493.25 +2.6%
TeamLease Services Ltd. Consolidated 2020-03 6.75 4,137.60 -2.8%
Just Dial Ltd. Consolidated 2020-03 24.85 965.50 +0.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Syngene International Ltd. Consolidated 2021-03 15.40 640.00 +0.1%
Quess Corp Ltd. Consolidated 2020-03 -5.79 880.65 +1.6%
RattanIndia Enterprises Ltd. Consolidated 2020-03 0.63 66.20 -1.0%
Sun Pharma Advanced Research Company Ltd. Standalone 2020-03 -178.22 280.50 +3.8%
SIS Ltd. Consolidated 2021-03 21.05 493.25 +2.6%
TeamLease Services Ltd. Consolidated 2020-03 16.25 4,137.60 -2.8%
Just Dial Ltd. Consolidated 2020-03 31.48 965.50 +0.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Syngene International Ltd. Consolidated 2021-03 2,184.30 640.00 +0.1%
Quess Corp Ltd. Consolidated 2020-03 10,991.48 880.65 +1.6%
RattanIndia Enterprises Ltd. Consolidated 2020-03 66.20 -1.0%
Sun Pharma Advanced Research Company Ltd. Standalone 2020-03 76.81 280.50 +3.8%
SIS Ltd. Consolidated 2021-03 9,127.30 493.25 +2.6%
TeamLease Services Ltd. Consolidated 2020-03 5,200.72 4,137.60 -2.8%
Just Dial Ltd. Consolidated 2020-03 953.11 965.50 +0.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Syngene International Ltd. Consolidated 2021-03 404.90 640.00 +0.1%
Quess Corp Ltd. Consolidated 2020-03 -418.05 880.65 +1.6%
RattanIndia Enterprises Ltd. Consolidated 2020-03 -0.38 66.20 -1.0%
Sun Pharma Advanced Research Company Ltd. Standalone 2020-03 -312.40 280.50 +3.8%
SIS Ltd. Consolidated 2021-03 366.66 493.25 +2.6%
TeamLease Services Ltd. Consolidated 2020-03 37.06 4,137.60 -2.8%
Just Dial Ltd. Consolidated 2020-03 272.31 965.50 +0.1%